貨號:GS40819
Ziltivekimab (formerly known as MEDI-5117) is an investigational human monoclonal antibody that targets and neutralizes interleukin-6 (IL-6). It is being developed primarily for the treatment of chronic inflammatory diseases, with a key focus on reducing cardiovascular risk in patients with chronic kidney disease and systemic inflammation, by modulating the IL-6 signaling pathway.
武漢邁思生物科技有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!
冉凱凱